|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:C10AX14
|
|
gptkbp:brand
|
gptkb:Praluent
|
|
gptkbp:CASNumber
|
gptkb:1245916-14-6
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
17-20 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
alirocumab
|
|
gptkbp:indication
|
gptkb:heterozygous_familial_hypercholesterolemia
clinical atherosclerotic cardiovascular disease
|
|
gptkbp:KEGGID
|
D10541
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
IgG1 monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
PCSK9 inhibitor
|
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108708
gptkb:DB09278
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
influenza
injection site reaction
allergic reactions
nasopharyngitis
|
|
gptkbp:target
|
gptkb:PCSK9
|
|
gptkbp:UNII
|
U7I1Y6M5F7
|
|
gptkbp:usedFor
|
gptkb:familial_hypercholesterolemia
cardiovascular disease risk reduction
|
|
gptkbp:bfsParent
|
gptkb:Praluent
|
|
gptkbp:bfsLayer
|
6
|